{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T08:49:36Z","timestamp":1781426976047,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Provincial Natural Science Foundation of China","award":["2023J01657"],"award-info":[{"award-number":["2023J01657"]}]},{"name":"Provincial Key Clinical Specialty in Interventional Radiology","award":["2128200744"],"award-info":[{"award-number":["2128200744"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29568-0","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T10:24:33Z","timestamp":1764066273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KAL suppresses cholangiocarcinoma growth via downregulating miR-21 and modulating the PTEN\/AKT signaling pathway"],"prefix":"10.1038","volume":"15","author":[{"given":"Jingyao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leye","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"24","key":"29568_CR1","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1200\/JCO.21.02576","volume":"40","author":"AJ Scott","year":"2022","unstructured":"Scott, A. J., Sharman, R. & Shroff, R. T. Precision medicine in biliary tract Cancer. J. Clin. Oncol. 40 (24), 2716\u20132734 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"29568_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5582\/bst.2020.03010","volume":"14","author":"Y Chen","year":"2020","unstructured":"Chen, Y., Xu, Y. & Zhang, Y. Current status of laparoscopic radical hilar cholangiocarcinoma in Mainland China. Biosci. Trends. 14 (3), 168\u2013173 (2020).","journal-title":"Biosci. Trends"},{"issue":"1","key":"29568_CR3","first-page":"18","volume":"3","author":"KC Soares","year":"2014","unstructured":"Soares, K. C. et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg. Nutr. 3 (1), 18\u201334 (2014).","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"1","key":"29568_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio, P. et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J. Hepatol. 71 (1), 104\u2013114 (2019).","journal-title":"J. Hepatol."},{"issue":"5","key":"29568_CR5","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","volume":"27","author":"A Elvevi","year":"2022","unstructured":"Elvevi, A. et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann. Hepatol. 27 (5), 100737 (2022).","journal-title":"Ann. Hepatol."},{"issue":"2","key":"29568_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"SI Ilyas","year":"2018","unstructured":"Ilyas, S. I. et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15 (2), 95\u2013111 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"29568_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","volume":"145","author":"SI Ilyas","year":"2013","unstructured":"Ilyas, S. I. & Gores, G. J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145 (6), 1215\u20131229 (2013).","journal-title":"Gastroenterology"},{"issue":"2","key":"29568_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.09.008","volume":"379","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 379 (2), 198\u2013205 (2016).","journal-title":"Cancer Lett."},{"issue":"5","key":"29568_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha, S. K. et al. Forty-Year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the Rise. Oncologist 21 (5), 594\u2013599 (2016).","journal-title":"Oncologist"},{"key":"29568_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000312694","volume":"39","author":"GS Maccoll","year":"2010","unstructured":"Maccoll, G. S., Quinton, R. & Bulow, H. E. Biology of KAL1 and its orthologs: implications for X-linked Kallmann syndrome and the search for novel candidate genes. Front. Horm. Res. 39, 62\u201377 (2010).","journal-title":"Front. Horm. Res."},{"key":"29568_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13023-015-0287-9","volume":"10","author":"J Sarfati","year":"2015","unstructured":"Sarfati, J. et al. Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life. Orphanet J. Rare Dis. 10, 71 (2015).","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"29568_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41598-019-57040-3","volume":"10","author":"S Matsushima","year":"2020","unstructured":"Matsushima, S. et al. Anosmin-1 activates vascular endothelial growth factor receptor and its related signaling pathway for olfactory bulb angiogenesis. Sci. Rep. 10 (1), 188 (2020).","journal-title":"Sci. Rep."},{"key":"29568_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.metabol.2017.10.012","volume":"86","author":"MI Stamou","year":"2018","unstructured":"Stamou, M. I. & Georgopoulos, N. A. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Metabolism 86, 124\u2013134 (2018).","journal-title":"Metabolism"},{"issue":"2","key":"29568_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jop.12206","volume":"44","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. Decreased expression of Kallmann syndrome 1 sequence gene (KAL1) contributes to oral squamous cell carcinoma progression and significantly correlates with poorly differentiated grade. J. Oral Pathol. Med. 44 (2), 109\u2013114 (2015).","journal-title":"J. Oral Pathol. Med."},{"issue":"6","key":"29568_CR15","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.3892\/ijo.2015.2965","volume":"46","author":"Y Tanaka","year":"2015","unstructured":"Tanaka, Y. et al. Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. Int. J. Oncol. 46 (6), 2546\u20132554 (2015).","journal-title":"Int. J. Oncol."},{"issue":"1","key":"29568_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00429-014-0904-8","volume":"221","author":"D Garc\u00eda-Gonz\u00e1lez","year":"2016","unstructured":"Garc\u00eda-Gonz\u00e1lez, D. et al. Anosmin-1 over-expression increases adult neurogenesis in the subventricular zone and neuroblast migration to the olfactory bulb. Brain Struct. Funct. 221 (1), 239\u2013260 (2016).","journal-title":"Brain Struct. Funct."},{"issue":"7","key":"29568_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s13205-025-04361-y","volume":"15","author":"X Zhou","year":"2025","unstructured":"Zhou, X. et al. Comprehensive analysis of anosmin-1 as a potential biomarker and its correlation with epithelial-mesenchymal transition in advanced gastric cancer. 3 Biotech. 15 (7), 222 (2025).","journal-title":"3 Biotech."},{"key":"29568_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fsurg.2016.00056","volume":"3","author":"NL Martirosyan","year":"2016","unstructured":"Martirosyan, N. L. et al. The role of MicroRNA markers in the Diagnosis, Treatment, and outcome prediction of spinal cord Injury. Front. Surg. 3, 56 (2016).","journal-title":"Front. Surg."},{"issue":"1","key":"29568_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-021-00272-1","volume":"9","author":"AE Jenike","year":"2021","unstructured":"Jenike, A. E. & Halushka, M. K. miR-21: a non-specific biomarker of all maladies. Biomark. Res. 9 (1), 18 (2021).","journal-title":"Biomark. Res."},{"issue":"21","key":"29568_CR20","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.4155\/fmc-2021-0096","volume":"13","author":"A Singh","year":"2021","unstructured":"Singh, A. et al. The role of microRNA-21 in the onset and progression of cancer. Future Med. Chem. 13 (21), 1885\u20131906 (2021).","journal-title":"Future Med. Chem."},{"issue":"1","key":"29568_CR21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4103\/0973-1482.193125","volume":"14","author":"CH Liu","year":"2018","unstructured":"Liu, C. H. et al. Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma. J. Cancer Res. Ther. 14 (1), 220\u2013225 (2018).","journal-title":"J. Cancer Res. Ther."},{"issue":"8","key":"29568_CR22","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.18632\/oncotarget.3465","volume":"6","author":"LJ Wang","year":"2015","unstructured":"Wang, L. J. et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 6 (8), 5932\u20135946 (2015).","journal-title":"Oncotarget"},{"key":"29568_CR23","doi-asserted-by":"crossref","unstructured":"Nguyen Huu, T. et al. Redox regulation of PTEN by Peroxiredoxins. Antioxid. (Basel), 10(2), 302\u2013315 (2021).","DOI":"10.3390\/antiox10020302"},{"issue":"1","key":"29568_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-023-02699-w","volume":"42","author":"W Liao","year":"2023","unstructured":"Liao, W. et al. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN\/AKT pathway in intrahepatic cholangiocarcinoma. J. Exp. Clin. Cancer Res. 42 (1), 125 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"29568_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.path.2023.04.012","volume":"16","author":"T El Jabbour","year":"2023","unstructured":"El Jabbour, T., Molnar, A. & Lagana, S. M. Challenges in diagnosing and reporting Cholangiocarcinoma. Surg. Pathol. Clin. 16 (3), 599\u2013608 (2023).","journal-title":"Surg. Pathol. Clin."},{"issue":"2","key":"29568_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.suc.2018.12.004","volume":"99","author":"AS Khan","year":"2019","unstructured":"Khan, A. S. & Dageforde, L. A. Cholangiocarcinoma. Surg. Clin. North. Am. 99 (2), 315\u2013335 (2019).","journal-title":"Surg. Clin. North. Am."},{"issue":"1","key":"29568_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12885-019-5391-0","volume":"19","author":"PL Labib","year":"2019","unstructured":"Labib, P. L., Goodchild, G. & Pereira, S. P. Molecular pathogenesis of Cholangiocarcinoma. BMC Cancer. 19 (1), 185 (2019).","journal-title":"BMC Cancer"},{"issue":"8","key":"29568_CR28","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1136\/gutjnl-2022-327099","volume":"71","author":"RIR Macias","year":"2022","unstructured":"Macias, R. I. R. et al. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 71 (8), 1669\u20131683 (2022).","journal-title":"Gut"},{"issue":"7838","key":"29568_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41586-020-2884-6","volume":"588","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature 588 (7838), 491\u2013497 (2020).","journal-title":"Nature"},{"key":"29568_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ctrv.2018.11.001","volume":"72","author":"F Corti","year":"2019","unstructured":"Corti, F. et al. Targeting the PI3K\/AKT\/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treat. Rev. 72, 45\u201355 (2019).","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"29568_CR31","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jpp\/rgab036","volume":"73","author":"B Acharya","year":"2021","unstructured":"Acharya, B., Chaijaroenkul, W. & Na-Bangchang, K. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K\/AKT\/mTOR and p38MAPK signalling pathways. J. Pharm. Pharmacol. 73 (9), 1191\u20131200 (2021).","journal-title":"J. Pharm. Pharmacol."},{"key":"29568_CR32","doi-asserted-by":"publisher","first-page":"154575","DOI":"10.1016\/j.phymed.2022.154575","volume":"109","author":"L Li","year":"2023","unstructured":"Li, L. et al. Triptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing Glycolysis via the AKT\/mTOR pathway. Phytomedicine 109, 154575 (2023).","journal-title":"Phytomedicine"},{"issue":"2","key":"29568_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1159\/000494183","volume":"50","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Tip60 suppresses cholangiocarcinoma proliferation and metastasis via PI3k-AKT. Cell. Physiol. Biochem. 50 (2), 612\u2013628 (2018).","journal-title":"Cell. Physiol. Biochem."},{"issue":"4","key":"29568_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/nat.2020.0914","volume":"31","author":"N Arghiani","year":"2021","unstructured":"Arghiani, N. & Matin, M. M. miR-21: A key small molecule with great effects in combination cancer Therapy. Nucleic Acid Ther. 31 (4), 271\u2013283 (2021).","journal-title":"Nucleic Acid Ther."},{"key":"29568_CR35","doi-asserted-by":"publisher","first-page":"175233","DOI":"10.1016\/j.ejphar.2022.175233","volume":"932","author":"T Akhtarkhavari","year":"2022","unstructured":"Akhtarkhavari, T., Bahrami, A. R. & Matin, M. M. Downregulation of miR-21 as a promising strategy to overcome drug resistance in cancer. Eur. J. Pharmacol. 932, 175233 (2022).","journal-title":"Eur. J. Pharmacol."},{"issue":"19","key":"29568_CR36","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1007\/s00018-018-2877-x","volume":"75","author":"C Bica-Pop","year":"2018","unstructured":"Bica-Pop, C. et al. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell. Mol. Life Sci. 75 (19), 3539\u20133551 (2018).","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"29568_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2174\/1566523217666170102105119","volume":"16","author":"S Javanmardi","year":"2017","unstructured":"Javanmardi, S. et al. miR-21, an oncogenic target MiRNA for cancer therapy: molecular mechanisms and recent advancements in chemo and Radio-resistance. Curr. Gene Ther. 16 (6), 375\u2013389 (2017).","journal-title":"Curr. Gene Ther."},{"issue":"6","key":"29568_CR38","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1541-7786.MCR-13-0419","volume":"12","author":"L Lu","year":"2014","unstructured":"Lu, L. et al. miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol. Cancer Res. 12 (6), 890\u2013900 (2014).","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"29568_CR39","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3892\/ijo.2017.3876","volume":"50","author":"CH Liu","year":"2017","unstructured":"Liu, C. H. et al. miR-21 and KLF4 jointly augment epithelial\u2013mesenchymal transition via the Akt\/ERK1\/2 pathway. Int. J. Oncol. 50 (4), 1109\u20131115 (2017).","journal-title":"Int. J. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29568-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29568-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29568-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:02:22Z","timestamp":1777402942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29568-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29568"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29568-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiment in this study followed the 3Rs guideline (Replacement, Reduction, Refinement) and was approved by the IACUC of Fujian Medical University Union Hospital. The approval number is FJMU 2023-Y-0963, and the approval date is 28 July 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to partipate"}}],"article-number":"45326"}}